Tumour-associated trypsin inhibitor TATI is a prognostic marker in colorectal cancer

Oncology

Volumn 82, Issue 4, 2012, Pages 234-241

  Koskensalo, Selja ^a   Hagström, Jaana ^a   Louhimo, Johanna ^a   Stenman, Ulf Håkan ^b   Haglund, Caj ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Colorectal cancer; Immunohistochemistry; Trypsinogen 1; Trypsinogen 2; Tumour associated trypsin inhibitor

Indexed keywords

APROTININ; PROTEIN TRYPSINOGEN 1; PROTEIN TRYPSINOGEN 2; TRYPSINOGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TRYPSIN; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TRYPSINOGEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859701684     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336080     Document Type: Article

References (46)

1. Koivunen E, Ristimaki A, Itkonen O, Osman S, Vuento M, Stenman UH: Tumour-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 1991; 51: 2107-2112.
2. Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen YT, Bergmann U, et al: Activation of type IV procollagenases by human tumourassociated trypsin-2. J Biol Chem 1997; 272: 21067-21074. (Pubitemid 27373964)
3. Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, et al: Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 2000; 86: 577-581. (Pubitemid 30249741)
4. Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, et al: The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 2001; 84: 1363-1371. (Pubitemid 32522105)
5. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, et al: Tumour-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 2003; 42: 5414-5420. (Pubitemid 36560438)
6. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, et al: Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 2003; 199: 176-184. (Pubitemid 36176023)
7. Paju A, Stenman UH: Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 2006; 43: 103-142. (Pubitemid 43860448)
8. Koshikawa N, Hasegawa S, Nagashima Y, Mitsuhashi K, Tsubota Y, Miyata S, et al: Expression of trypsin by epithelial cells of various tissues, leukocytes, and neurons in human and mouse. Am J Pathol 1998; 153: 937-944. (Pubitemid 28419046)
9. Koshikawa N, Nagashima Y, Miyagi Y, Mizushima H, Yanoma S, Yasumitsu H, et al: Expression of trypsin in vascular endothelial cells. FEBS Lett 1997; 409: 442-448. (Pubitemid 27285902)
10. Stenman UH, Koivunen E, Vuento M: Characterization of a tumour-associated serine protease. Biol Chem Hoppe Seyler 1988; 369(suppl):9-14.
11. Stenman M, Paju A, Hanemaaijer R, Tervahartiala T, Leminen A, Stenman UH, et al: Collagenases (MMP-1, -8 and -13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts. Tumour Biol 2003; 24: 9-12. (Pubitemid 36578813)
12. Fujimura T, Ohta T, Kitagawa H, Fushida S, Nishimura GI, Yonemura Y, et al: Trypsinogen expression and early detection for peritoneal dissemination in gastric cancer. J Surg Oncol 1998; 69: 71-75. (Pubitemid 28515963)
13. Williams SJ, Gotley DC, Antalis TM: Human trypsinogen in colorectal cancer. Int J Cancer 2001; 93: 67-73. (Pubitemid 32539503)
14. Oyama K, Ohta T, Nishimura GI, Elnemr A, Yasui T, Fujimura T, et al: Trypsinogen expression in colorectal cancers. Int J Mol Med 2000; 6: 543-548.
15. Hirahara F, Miyagi Y, Miyagi E, Yasumitsu H, Koshikawa N, Nagashima Y, et al: Trypsinogen expression in human ovarian carcinomas. Int J Cancer 1995; 63: 176-181.
16. Ohta T, Terada T, Nagakawa T, Tajima H, Itoh H, Fonseca L, et al: Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994; 69: 152-156. (Pubitemid 24021839)
17. Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D: A tumour-suppressive role for trypsin in human cancer progression. Cancer Res 2003; 63: 6575-6578. (Pubitemid 37322934)
18. Terada T, Ohta T, Minato H, Nakanuma Y: Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 1995; 26: 746-752.
19. Kawano N, Osawa H, Ito T, Nagashima Y, Hirahara F, Inayama Y, et al: Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997; 28: 613-622. (Pubitemid 27213059)
20. Koivunen E, Huhtala ML, Stenman UH: Human ovarian tumour-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989; 264: 14095-14099. (Pubitemid 19214237)
21. Stenman UH, Huhtala ML, Koistinen R, Seppala M: Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 1982; 30: 53-57. (Pubitemid 12044235)
22. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH: Purification and characterization of a tumour-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982; 257: 13713-13716. (Pubitemid 13187134)
23. Marchbank T, Chinery R, Hanby AM, Poulsom R, Elia G, Playford RJ: Distribution and expression of pancreatic secretory trypsin inhibitor and its possible role in epithelial restitution. Am J Pathol 1996; 148: 715-722. (Pubitemid 126660664)
24. Stenman UH, Koivunen E, Itkonen O: Biology and function of tumour-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest Suppl 1991; 207: 5-9.
25. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O: Tumourassociated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 1994; 70: 1188-1190. (Pubitemid 24358961)
26. Venesmaa P, Stenman UH, Forss M, Leminen A, Lehtovirta P, Vartiainen J, et al: Preoperative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in stage III epithelial ovarian cancer. Br J Obstet Gynaecol 1998; 105: 508-511. (Pubitemid 28261380)
27. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, et al: Expression of trypsinogen-1, trypsinogen-2, and tumour-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 2004; 10: 4761-4768. (Pubitemid 38955528)
28. Kelloniemi E, Rintala E, Finne P, Stenman UH, Finnbladder Group: Tumour-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 2003; 62: 249-253. (Pubitemid 36952071)
29. Loizate Toricaguena A, Lamiquiz Vallejo A, Dominguez Merru-Urrutia MJ, Legorburu Escudero JF: Tumour-associated trypsin inhibitor (TATI) in benign and malignant gastric disease. Scand J Clin Lab Invest Suppl 1991; 207: 59-62.
30. Piantino P, Arosaio E: Tumour-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases. Scand J Clin Lab Invest Suppl 1991; 207: 67-69.
31. Wiksten JP, Lundin J, Nordling S, Kokkola A, Stenman UH, Haglund C: High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 2005; 46: 380-388. (Pubitemid 40516753)
32. Hotakainen K, Bjartell A, Sankila A, Jarvinen R, Paju A, Rintala E, et al: Differential expression of trypsinogen and tumour-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 2006; 28: 95-101.
33. Davis NC, Evans EB, Cohen JR, Theile DE: Staging of colorectal cancer. The Australian clinico-pathological staging (ACPS) system compared with Dukes' system. Dis Colon Rectum 1984; 27: 707-713. (Pubitemid 15206681)
34. Itkonen O, Koivunen E, Hurme M, Alfthan H, Schroder T, Stenman UH: Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 1990; 115: 712-718. (Pubitemid 20213162)
35. Osman S, Turpeinen U, Itkonen O, Stenman UH: Optimization of a time-resolved immunofluorometric assay for tumour-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 1993; 161: 97-106.
36. Stenman UH: Tumour-associated trypsin inhibitor and tumour-associated trypsin. Scand J Clin Lab Invest Suppl 1990; 201: 93-101. (Pubitemid 20271065)
37. Higashiyama M, Monden T, Tomita N, Murotani M, Kawasaki Y, Morimoto H, et al: Expression of pancreatic secretory trypsin inhibitor (PSTI) in colorectal cancer. Br J Cancer 1990; 62: 954-958.
38. Gaber A, Johansson M, Stenman UH, Hotakainen K, Ponten F, Glimelius B, et al: High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 2009; 100: 1540-1548.
39. Solakidi S, Tiniakos DG, Petraki K, Stathopoulos GP, Markaki I, Androulakis G, et al: Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. Histol Histopathol 2003; 18: 1181-1188. (Pubitemid 37265020)
40. Pasanen P, Eskelinen M, Kulju A, Penttila I, Janatuinen E, Alhava E: Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Scand J Clin Lab Invest 1995; 55: 119-124.
41. Coussens LM, Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904. (Pubitemid 27017088)
42. Gouyer V, Fontaine D, Dumont P, de Wever O, Fontayne-Devaud H, Leteurtre E, et al: Autocrine induction of invasion and metastasis by tumour-associated trypsin inhibitor in human colon cancer cells. Oncogene 2008; 27: 4024-4033. (Pubitemid 351931988)
43. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, et al: Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 2009; 7: 1572-1581.
44. Oikawa T, Hitomi J, Kono A, Kaneko E, Yamaguchi K: Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int J Pancreatol 1995; 18: 15-23.
45. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Buchler MW: Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med (Berl) 1996; 74: 35-42. (Pubitemid 26034370)
46. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992; 90: 1352-1360.